Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, Inc. (Nasdaq: SEER), a life sciences company specializing in proteomics, will release its financial results for Q1 2023 after market close on May 9, 2023. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investor section of their website. Seer’s Proteograph™ Product Suite offers a breakthrough solution for unbiased proteomic analysis, streamlining laboratory workflows with engineered nanoparticles, consumables, automation, and software. Designed for research applications only, the Proteograph enables deep analysis in hours, enhancing lab efficiency.
Seer Inc. (NASDAQ: SEER) announced a study in PLOS One revealing new protein variants associated with non-small cell lung cancer (NSCLC) using the Proteograph Product Suite. Collaborating with Memorial Sloan Kettering Cancer Center, researchers identified four protein isoforms linked to NSCLC progression, highlighting their potential as new biomarkers. Notably, the short protein isoform of BMP1 was found more frequently in late-stage NSCLC patients. The analysis included 188 plasma samples from NSCLC patients and controls. Results underscore the importance of unbiased proteomics for advancing cancer research and diagnosis.
Seer Inc. (Nasdaq: SEER) reported a significant revenue increase of 134% in 2022, reaching $15.5 million, with fourth-quarter revenue of $4.6 million, a 50% year-over-year rise. Instruments shipped rose 129% with a total of 39 units by year-end. Despite growth, the company faced a net loss of $93.0 million for the year. Operating expenses surged to $104.3 million
, leading to a gross profit margin of 46%. For 2023, Seer forecasts revenue between $23 million and $25 million, indicating a growth rate of 48% to 61%.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
